. 2014 Aug 12;2014:541950. doi: 10.1155/2014/541950

Table 2.

Pooled RR of acotiamide versus placebo for elimination of FD symptoms by Mantel-Haenszel fixed-effect model.

Groups and subgroups	Number of trials [reference]	Number of patients	RR; 95% CI	P value	Test of heterogeneity
Groups and subgroups	Number of trials [reference]	Number of patients	RR; 95% CI	P value	P value	I ²
PDS	2 [16]	396	1.29; 1.09–1.53	0.003	0.830	0%
50 mg, tid	1 [16]	151	1.08; 0.76–1.53	0.660	NA	NA
100 mg, tid	2 [16]	206	1.41; 1.07–1.85	0.010	0.860	0%
300 mg, tid	2 [16]	218	1.33; 1.01–1.75	0.040	0.960	0%
EPS	2 [16]	320	0.92; 0.76–1.11	0.390	0.970	0%
50 mg, tid	1 [16]	73	0.88; 0.58–1.34	0.550	NA	NA
100 mg, tid	2 [16]	184	0.96; 0.72–1.29	0.800	0.520	0%
300 mg, tid	2 [16]	192	0.90; 0.67–1.21	0.480	0.990	0%
Postprandial fullness^a	3 [16, 25]	1438	1.90; 1.37–2.64	<0.001	0.030	60%
50 mg, tid	1 [16]	149	3.19; 1.36–7.44	0.007	NA	NA
100 mg, tid	3 [16, 25]	1190	1.75; 1.14–2.66	0.010	0.060	64%
300 mg, tid	2 [16]	337	2.05; 0.79–5.34	0.140	0.040	77%
Upper abdominal bloating	3 [16, 25]	1232	1.30; 1.12–1.50	<0.001	0.930	0%
50 mg, tid	1 [16]	135	1.26; 0.79–2.01	0.330	NA	NA
100 mg, tid	3 [16, 25]	1001	1.29; 1.08–1.54	0.005	0.550	0%
300 mg, tid	2 [16]	310	1.34; 0.99–1.80	0.060	0.730	0%
Early satiety	3 [16, 25]	1206	1.39; 1.19–1.61	<0.001	0.830	0%
50 mg, tid	1 [16]	133	1.60; 0.95–2.70	0.080	NA	NA
100 mg, tid	3 [16, 25]	1002	1.39; 1.16–1.67	<0.001	0.450	0%
300 mg, tid	2 [16]	285	1.29; 0.94–1.76	0.110	0.830	0%

^aMantel-Haenszel random-effects model.

CI, confidential interval; FD, functional dyspepsia; NA, not applicable; RR, risk ratio; and tid, three times daily.